Martha Gonzalez

520 total citations
21 papers, 408 citations indexed

About

Martha Gonzalez is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Martha Gonzalez has authored 21 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 7 papers in Molecular Biology and 6 papers in Oncology. Recurrent topics in Martha Gonzalez's work include Prostate Cancer Treatment and Research (9 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Martha Gonzalez is often cited by papers focused on Prostate Cancer Treatment and Research (9 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Pharmacogenetics and Drug Metabolism (5 papers). Martha Gonzalez collaborates with scholars based in United States, Belgium and Canada. Martha Gonzalez's co-authors include Milin Acharya, Ronald P. de Vries, NamPhuong Tran, James Jiao, Margaret K. Yu, Thian Kheoh, Hans Stieltjes, Caly Chien, Christian Lopez and Johan W. Smit and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and European Urology.

In The Last Decade

Martha Gonzalez

20 papers receiving 396 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Martha Gonzalez United States	11	197	137	125	87	70	21	408
James Jiao United States	13	139 0.7×	144 1.1×	115 0.9×	74 0.9×	74 1.1×	18	628
Yoshiaki Ohtsu Japan	10	184 0.9×	99 0.7×	82 0.7×	74 0.9×	87 1.2×	26	477
Hille Gieschen Germany	12	219 1.1×	90 0.7×	72 0.6×	101 1.2×	105 1.5×	16	455
Hans Stieltjes Belgium	17	132 0.7×	169 1.2×	247 2.0×	54 0.6×	154 2.2×	26	628
Masaru Hasumi Japan	14	138 0.7×	247 1.8×	68 0.5×	51 0.6×	106 1.5×	26	638
Thomas Spires United States	12	268 1.4×	170 1.2×	78 0.6×	37 0.4×	182 2.6×	15	790
Joline S.W. Lind Netherlands	14	315 1.6×	184 1.3×	108 0.9×	86 1.0×	276 3.9×	20	656
Charles S. Dai United States	9	410 2.1×	240 1.8×	95 0.8×	39 0.4×	152 2.2×	25	633
Robert E. Fricke Germany	7	128 0.6×	51 0.4×	42 0.3×	60 0.7×	90 1.3×	16	287
Olaf Prien Germany	10	141 0.7×	98 0.7×	41 0.3×	68 0.8×	56 0.8×	16	353

Countries citing papers authored by Martha Gonzalez

Since Specialization

Citations

This map shows the geographic impact of Martha Gonzalez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martha Gonzalez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martha Gonzalez more than expected).

Fields of papers citing papers by Martha Gonzalez

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martha Gonzalez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martha Gonzalez. The network helps show where Martha Gonzalez may publish in the future.

Co-authorship network of co-authors of Martha Gonzalez

This figure shows the co-authorship network connecting the top 25 collaborators of Martha Gonzalez. A scholar is included among the top collaborators of Martha Gonzalez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martha Gonzalez. Martha Gonzalez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gonzalez, Martha, et al.. (2025). Assessment of Food Effect and pH‐Dependent Drug–Drug Interactions of Fruquintinib in Healthy Subjects. Clinical and Translational Science. 18(3). e70168–e70168.

Gonzalez, Martha, et al.. (2025). Evaluation of Potential Effects of CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Fruquintinib in Healthy Subjects. Clinical Pharmacology in Drug Development. 14(8). 605–613. 1 indexed citations

Wang‐Gillam, Andrea, et al.. (2023). Phase 1/1b open-label, dose-escalation study of fruquintinib in patients with advanced solid tumors in the United States. Investigational New Drugs. 41(6). 851–860. 7 indexed citations

Poggesi, Italo, Belén Valenzuela, Danièle Ouellet, et al.. (2019). Population pharmacokinetics of trabectedin in adolescent patients with cancer. Cancer Chemotherapy and Pharmacology. 84(4). 707–717. 2 indexed citations

Li, Lilian Y., Yue Guo, Martha Gonzalez, & Danièle Ouellet. (2019). Effect of Plasma Protein Binding on the Pharmacokinetics of Erdafitinib: Results of an Integrated Cross‐Study Analysis. The Journal of Clinical Pharmacology. 60(3). 391–399. 8 indexed citations

Posadas, Edwin M., Kim N., Ronald de Wit, et al.. (2017). Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.. Journal of Clinical Oncology. 35(6_suppl). 173–173. 7 indexed citations

Soria, Jean‐Charles, John H. Strickler, Ramaswamy Govindan, et al.. (2017). Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).. Journal of Clinical Oncology. 35(15_suppl). 4074–4074. 20 indexed citations

Monbaliu, Johan, Martha Gonzalez, Carlo Sensenhauser, et al.. (2016). In Vitro and In Vivo Drug-Drug Interaction Studies to Assess the Effect of Abiraterone Acetate, Abiraterone, and Metabolites of Abiraterone on CYP2C8 Activity. Drug Metabolism and Disposition. 44(10). 1682–1691. 23 indexed citations

Tagawa, Scott T., Edwin M. Posadas, Justine Y. Bruce, et al.. (2016). Phase 1b Study of Abiraterone Acetate Plus Prednisone and Docetaxel in Patients with Metastatic Castration-resistant Prostate Cancer. European Urology. 70(5). 718–721. 15 indexed citations

10.

N., Kim, Jennifer L. Spratlin, Christian Kollmannsberger, et al.. (2015). Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration‐resistant prostate cancer. The Journal of Clinical Pharmacology. 55(12). 1406–1414. 82 indexed citations

11.

Posadas, Edwin M., Kim N., Ronald de Wit, et al.. (2015). Phase 1b study of ARN-509 with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 33(15_suppl). 5028–5028. 2 indexed citations

12.

Gonzalez, Martha, Laura Goracci, Gabriele Cruciani, & Italo Poggesi. (2014). Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease. Expert Opinion on Drug Metabolism & Toxicology. 10(10). 1397–1408. 15 indexed citations

13.

Solanki, Bhavna, et al.. (2014). Pharmacokinetics of rabeprazole granules versus tablets, and the effect of food on the pharmacokinetics of rabeprazole granules in healthy adults—cross‐study comparison. Clinical Pharmacology in Drug Development. 3(5). 406–416. 3 indexed citations

14.

Tagawa, Scott T., David M. Nanus, Edwin M. Posadas, et al.. (2014). Evaluating the safety of abiraterone acetate (AA) and docetaxel (D) administered in combination in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 32(4_suppl). 205–205. 1 indexed citations

15.

Marbury, Thomas, Eric Lawitz, Martha Gonzalez, et al.. (2013). Single‐dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment. The Journal of Clinical Pharmacology. 54(7). 732–741. 23 indexed citations

16.

Acharya, Milin, Martha Gonzalez, Geert Mannens, et al.. (2012). A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica. 43(4). 379–389. 53 indexed citations

17.

Acharya, Milin, et al.. (2012). Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men. Cancer Chemotherapy and Pharmacology. 69(6). 1583–1590. 42 indexed citations

18.

Tolcher, Anthony W., K. N., Neal D. Shore, et al.. (2012). Effect of abiraterone acetate plus prednisone on the QT interval in patients with metastatic castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. 70(2). 305–313. 27 indexed citations

19.

Zannikos, Peter, Dennis R. Doose, G Leitz, et al.. (2011). Pharmacokinetics and Tolerability of Rabeprazole in Children 1 to 11 Years Old With Gastroesophageal Reflux Disease. Journal of Pediatric Gastroenterology and Nutrition. 52(6). 691–701. 16 indexed citations

20.

Gonzalez, Martha, Peter Zannikos, Allitia DiBernardo, H. Robert Brashear, & Jay Ariyawansa. (2011). Effect of Carisbamate on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Participants. The Journal of Clinical Pharmacology. 52(9). 1420–1429. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact